SCHEMBL2834430

SCHEMBL2834430

COC(=O)c1ccc(NC(=O)c2ccco2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 1.00
SMN1; SMN2 Q16637 5/20 1.00
NPC1 O15118 4/20 1.00
TP53 P04637 2/20 1.00
PSMD14 O00487 1/20 0.94
CACNA1B Q00975 1/20 0.94
APBA1 Q02410 1/20 0.94
KMT2A Q03164 6/20 0.81
MEN1 O00255 4/20 0.81
HTT P42858 1/20 0.72
ALDH1A1 P00352 3/20 0.71
HPGD P15428 2/20 0.71
APOBEC3G Q9HC16 1/20 0.69
GAA P10253 1/20 0.68
KDM4E B2RXH2 2/20 0.67
MAPT P10636 2/20 0.67
TSHR P16473 2/20 0.67
PKM P14618 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67
PTPN2 P17706 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15798361 0.87 SMN1; SMN2 (0.80) RAB9ASMN1; SMN2NPC1TP53PSMD14
SCHEMBL6819048 0.84 RAB9A (0.72) RAB9ASMN1; SMN2NPC1TP53PSMD14
SCHEMBL6633618 0.83 KMT2A (0.89) RAB9ASMN1; SMN2NPC1TP53PSMD14
SCHEMBL15056399 0.83 RAB9A (0.75) RAB9ASMN1; SMN2NPC1TP53PSMD14
SCHEMBL6816533 0.82 SMN1; SMN2 (0.84) RAB9ASMN1; SMN2NPC1TP53PSMD14
SCHEMBL8434936 0.81 RAB9A (0.75) RAB9ASMN1; SMN2NPC1TP53PSMD14
SCHEMBL24711259 0.81 SMN1; SMN2 (1.00) RAB9ASMN1; SMN2NPC1TP53PSMD14
SCHEMBL1846669 0.81 RAB9A (0.83) RAB9ASMN1; SMN2NPC1TP53KMT2A
SCHEMBL22823075 0.81 RAB9A (1.00) RAB9ASMN1; SMN2NPC1TP53KMT2A
SCHEMBL19994485 0.81 KMT2A (0.71) RAB9ASMN1; SMN2NPC1TP53PSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013093508-A2 WNT PATHWAY INHIBITORS OSLO UNIVERSITY HOSPITAL HF (NO) 2013-06-27 WO disclosed
WO-2013093508-A2 WNT PATHWAY INHIBITORS OSLO UNIVERSITY HOSPITAL HF (NO) 2013-06-27 WO disclosed
US-20100168101-A1 OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2010-07-01 US disclosed
US-7696231-B2 Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs) LABORATOIRES SERONO SA (CH) 2010-04-13 US disclosed
US-20050043388-A1 Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. 2005-02-24 US disclosed
EP-1439834-A1 OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) Applied Research Systems ARS Holding N.V. (AN) 2004-07-28 EP disclosed
WO-2003037328-A1 OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043388-A1 Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) PTPRO, PTPRE, PTPRZ1 RAB9A 3219/4885SMN1; SMN2 4885/4885NPC1 1600/4885
US-20100168101-A1 OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) PTPRO, PTPRE, PTPRZ1 RAB9A 3161/4885SMN1; SMN2 4885/4885NPC1 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.